Biriperone

Biriperone (compound 2) (i.p.; single dose) blocks conditioned avoidance response in rats, with an ED₅₀ of 0.09 mg/kg, indicating potent in vivo D₂ receptor antagonism and antipsychotic-like activity^[1].
Biriperone (i.p.; single dose) blocks secondary conditioned avoidance response in rats, with an ED₅₀ of 0.04 mg/kg, demonstrating efficacy in suppressing learned avoidance behaviors^[1].
Biriperone (i.p.; single dose) blocks unconditioned response in rats, with an ED₅₀ of 9.80 mg/kg, indicating a higher dose requirement for motor reflex suppression compared to conditioned responses^[1].
Biriperone (i.p.; single dose) reduces amphetamine-induced hyperactivity in mice, with an ED₅₀ of 0.75 mg/kg, confirming its in vivo D₂ receptor blocking activity in the mesolimbic pathway^[1].
Biriperone (i.p.; single dose) antagonizes amphetamine-induced toxicity in mice, with an ED₅₀ of 1.00 mg/kg, demonstrating protective effects against dopaminergic overstimulation^[1].
Biriperone (i.p.; single dose) induces motor incoordination in mice in the rota rod test, with an ED₅₀ of 2.55 mg/kg, indicating its potential for extrapyramidal side effects at higher doses^[1]. Biriperone (i.p.; single dose) induces catalepsy in rats, with an ED₅₀ of 0.86 mg/kg, and a catalepsy/CAR ED₅0 ratio of 9.5, suggesting a narrower therapeutic window for extrapyramidal side effects compared to compound 5^[1]. Biriperone (i.p.; single dose) reduces spontaneous motor activity in rodents[1].